Abstract
PURPOSE OF REVIEW: Multiple action drugs, such as azelastine, epinastine, ketotifen and olopatadine, have recently been suggested to combine antihistaminic effect, mast cell stabilization and anti-inflammatory action. This pharmaceutical class is, therefore, rapidly becoming the first choice for prevention and treatment for allergic conjunctivitis. RECENT FINDINGS: Increasing in-vitro studies have been performed to investigate the mast-cell-stabilizing effect of multiple action drugs. Most of the study results agree that these drugs are able to inhibit histamine and several neoformed mediators, including cytokines and arachidonic acid-derived products, from mast cells. However, the mechanisms of action have not yet fully been elucidated. Most of the results from clinical trials as well as the in-vivo experimental studies, including the conjunctival provocation model, support the evidence of a stabilizing effect of these drugs. SUMMARY: Evidence of a different inhibitory effect of multiple action compounds on the pro-inflammatory mediators released from the mast cells suggests the possibility to target different phases of the allergic reaction, leading to a potential improvement in the management of allergic patients.
| Original language | English |
|---|---|
| Pages (from-to) | 454-465 |
| Number of pages | 12 |
| Journal | Current Opinion in Allergy and Clinical Immunology |
| Volume | 9 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Oct 2009 |
Fingerprint
Keywords
- Azelastine
- Epinastine
- Ketotifen
- Mast cells
- Olopatadine
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Cite this
Multiple action agents and the eye : Do they really stabilize mast cells? / Lambiase, Alessandro; Micera, Alessandra; Bonini, Stefano.
In: Current Opinion in Allergy and Clinical Immunology, Vol. 9, No. 5, 10.2009, p. 454-465.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Multiple action agents and the eye
T2 - Do they really stabilize mast cells?
AU - Lambiase, Alessandro
AU - Micera, Alessandra
AU - Bonini, Stefano
PY - 2009/10
Y1 - 2009/10
N2 - PURPOSE OF REVIEW: Multiple action drugs, such as azelastine, epinastine, ketotifen and olopatadine, have recently been suggested to combine antihistaminic effect, mast cell stabilization and anti-inflammatory action. This pharmaceutical class is, therefore, rapidly becoming the first choice for prevention and treatment for allergic conjunctivitis. RECENT FINDINGS: Increasing in-vitro studies have been performed to investigate the mast-cell-stabilizing effect of multiple action drugs. Most of the study results agree that these drugs are able to inhibit histamine and several neoformed mediators, including cytokines and arachidonic acid-derived products, from mast cells. However, the mechanisms of action have not yet fully been elucidated. Most of the results from clinical trials as well as the in-vivo experimental studies, including the conjunctival provocation model, support the evidence of a stabilizing effect of these drugs. SUMMARY: Evidence of a different inhibitory effect of multiple action compounds on the pro-inflammatory mediators released from the mast cells suggests the possibility to target different phases of the allergic reaction, leading to a potential improvement in the management of allergic patients.
AB - PURPOSE OF REVIEW: Multiple action drugs, such as azelastine, epinastine, ketotifen and olopatadine, have recently been suggested to combine antihistaminic effect, mast cell stabilization and anti-inflammatory action. This pharmaceutical class is, therefore, rapidly becoming the first choice for prevention and treatment for allergic conjunctivitis. RECENT FINDINGS: Increasing in-vitro studies have been performed to investigate the mast-cell-stabilizing effect of multiple action drugs. Most of the study results agree that these drugs are able to inhibit histamine and several neoformed mediators, including cytokines and arachidonic acid-derived products, from mast cells. However, the mechanisms of action have not yet fully been elucidated. Most of the results from clinical trials as well as the in-vivo experimental studies, including the conjunctival provocation model, support the evidence of a stabilizing effect of these drugs. SUMMARY: Evidence of a different inhibitory effect of multiple action compounds on the pro-inflammatory mediators released from the mast cells suggests the possibility to target different phases of the allergic reaction, leading to a potential improvement in the management of allergic patients.
KW - Azelastine
KW - Epinastine
KW - Ketotifen
KW - Mast cells
KW - Olopatadine
UR - http://www.scopus.com/inward/record.url?scp=69749121407&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=69749121407&partnerID=8YFLogxK
U2 - 10.1097/ACI.0b013e3283303ebb
DO - 10.1097/ACI.0b013e3283303ebb
M3 - Article
C2 - 19652595
AN - SCOPUS:69749121407
VL - 9
SP - 454
EP - 465
JO - Current Opinion in Allergy and Clinical Immunology
JF - Current Opinion in Allergy and Clinical Immunology
SN - 1528-4050
IS - 5
ER -